<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">811</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2022-12-3-17-27</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The clinical significance of the features of the morphological study and immunohistochemical determination of pancytokeratin in the lymph nodes of the central zone in papillary thyroid cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Клиническое значение особенностей морфологического исследования и иммуногистохимического определения панцитокератина в лимфатических узлах центральной зоны при папиллярном раке щитовидной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4484-9423</contrib-id><name-alternatives><name xml:lang="en"><surname>Galushko</surname><given-names>D.  A.</given-names></name><name xml:lang="ru"><surname>Галушко</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>86 Profsoyuznaya St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, ул. Профсоюзная, 86</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0344-9738</contrib-id><name-alternatives><name xml:lang="en"><surname>Asmaryan</surname><given-names>H.  G.</given-names></name><name xml:lang="ru"><surname>Асмарян</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Hayk Garnikovich Asmaryan </p><p>86 Profsoyuznaya St., Moscow 117997</p></bio><bio xml:lang="ru"><p>Айк Гарникович Асмарян </p><p>117997 Москва, ул. Профсоюзная, 86</p></bio><email>asmaryan@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1193-352X</contrib-id><name-alternatives><name xml:lang="en"><surname>Melnikova</surname><given-names>N.  V.</given-names></name><name xml:lang="ru"><surname>Мельникова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>86 Profsoyuznaya St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, ул. Профсоюзная, 86</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2350-8141</contrib-id><name-alternatives><name xml:lang="en"><surname>Lazukina</surname><given-names>I.  A.</given-names></name><name xml:lang="ru"><surname>Лазукина</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>86 Profsoyuznaya St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997 Москва, ул. Профсоюзная, 86</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Scientific Center of Roentgenoradiology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-10-14" publication-format="electronic"><day>14</day><month>10</month><year>2022</year></pub-date><volume>12</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>17</fpage><lpage>27</lpage><history><date date-type="received" iso-8601-date="2022-12-13"><day>13</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-13"><day>13</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Galushko D.A., Asmaryan H.G., Melnikova N.V., Lazukina I.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Галушко Д.А., Асмарян А.Г., Мельникова Н.В., Лазукина И.А.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Galushko D.A., Asmaryan H.G., Melnikova N.V., Lazukina I.A.</copyright-holder><copyright-holder xml:lang="ru">Галушко Д.А., Асмарян А.Г., Мельникова Н.В., Лазукина И.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/811">https://ogsh.abvpress.ru/jour/article/view/811</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> papillary thyroid cancer is increasingly being detected at early stages when regional and distant metastases are absent per clinical examination. However, lymph nodes of the central zone can carry hidden metastases. frequency of such metastases is 22.3–46.7 %. maximally accurate identification of hidden metastases after lymph node dissection remains an important problem.</p><p><bold>Aim.</bold> тo evaluate the effect of histological examination characteristics and immunohistochemical measurement of pancytokeratin level on frequency of detection of papillary cancer hidden metastases in regional lymph nodes of the central zone in patients with clinical stage N0 papillary cancer.</p><p><bold>Materials and methods.</bold> The main group included 50 patients with stage ст1–2N0М0 primary papillary thyroid cancer. Dissected central lymph nodes of the patients prior to formalin fixation were extracted from the sample and inserted in individual paraffin blocks. Apart from standard histological examination, pancytokeratin level was measured immunohistochemically in the lymph nodes. The control group consisted of 200 patients for whom dissected central cell tissue was sectioned into blocks after formalin fixation. The number of lymph nodes in the dissected sample was measured by a pathomorphologist.</p><p><bold>Results.</bold> In the main group, the number of lymph nodes in the sample varied between 6 and 37 with mean of 20.7 ± 6.8; in the control group the number was lower: 3–25, mean 9.8 ± 5.1 (<italic>р</italic><italic> </italic>= 0.000). In the main group, hidden metastases were detected more frequently than in the control group: in 30 (60 %) and 68 (34 %) cases, respectively (<italic>р</italic> = 0.001). In 20 (40 %) patients, immunohistochemical examination showed new metastases. use of this method allowed to detect 1 to 7 additional metastases (mean 2.4 ± 1.5 lymph node lesions).</p><p><bold>Conclusion. </bold>use of targeted dissection with extraction of lymph nodes led to significant increase in their numbers in the samples, and immunohistochemical examination allowed to detect a large number of hidden metastases in the central lymph nodes.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> папиллярный рак щитовидной железы все чаще выявляется на ранних стадиях, когда регионарные и отдаленные метастазы по данным клинического обследования отсутствуют. Однако в лимфатических узлах центральной зоны могут возникать скрытые метастазы. частота их развития составляет 22,3–46,7 %. Максимально корректная идентификация скрытых метастазов после выполнения лимфодиссекции является актуальной проблемой.</p><p><bold>Цель исследования </bold>– оценить влияние особенностей гистологического исследования и определения уровня панцитокератина с помощью иммуногистохимического исследования на частоту выявления скрытых метастазов папиллярного рака в регионарных лимфатических узлах центральной зоны у больных папиллярным раком с клинической стадией N0.</p><p><bold>Материалы и методы.</bold> В основную группу включены 50 пациентов с впервые выявленным папиллярным раком щитовидной железы стадии ст1–2N0М0, у которых удаленные лимфатические узлы центральной зоны до фиксации в формалине выделяли из препарата и после фиксации помещали в отдельные парафиновые блоки. Кроме стандартного гистологического исследования в данной группе иммуногистохимическим методом определяли уровень панцитокератина в лимфатических узлах. Контрольную группу составили 200 пациентов, у которых удаленную центральную клетчатку после фиксации в формалине нарезали блоками. Количество лимфатических узлов в удаленном препарате определял патоморфолог.</p><p><bold>Результаты.</bold> В основной группе количество лимфатических узлов в препарате колебалось от 6 до 37 и в среднем составило 20,7 ± 6,8; в группе контроля данный показатель был меньше: 3–25, в среднем 9,8 ± 5,1 (<italic>р </italic>= 0,000). В основной группе скрытые метастазы выявлялись чаще, чем в контрольной: в 30 (60 %) и 68 (34 %) случаях соответственно (<italic>р</italic> = 0,001). у 20 (40 %) пациентов при иммуногистохимическом исследовании обнаружены новые метастазы. применение данного метода исследования позволило дополнительно выявить от 1 до 7 метастазов (в среднем 2,4 ± 1,5 пораженного лимфатического узла).</p><p><bold>Заключение. </bold>применение прицельной вырезки с выделением лимфатических узлов привело к значимому увеличению их числа в препарате, а проведение иммуногистохимического исследования позволило выявить большее количество скрытых метастазов в лимфатических узлах центральной зоны.</p></trans-abstract><kwd-group xml:lang="en"><kwd>papillary thyroid cancer</kwd><kwd>hidden lymphnode metastasis</kwd><kwd>immunohistochemical examination</kwd><kwd>pancytokeratin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>папиллярный рак щитовидной железы</kwd><kwd>скрытые метастазы в лимфатических узлах</kwd><kwd>иммуногистохимическое исследование</kwd><kwd>панцитокератин</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was carried out with the financial support of the Russian Scientific Center of Radiology, Ministry of Health of Russia.</funding-statement><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1.	Noone A.M., Howlader N., Krahcho M. et al. SEER Cancer Statistics Review, 1975–2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Bethesda, MD: National Cancer Institute, 2018. Available at: htths://seer.cancer.gov/csr/1975-2015/.</mixed-citation><mixed-citation xml:lang="ru">Noone A.M., Howlader N., Krahcho M. et al. SEER Cancer Statistics Review, 1975–2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Bethesda, MD: National Cancer Institute, 2018. Available at: htths://seer.cancer.gov/csr/1975-2015/.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Noguchi S., Noguchi A., Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 1970;26(5):1053–60. DOI: 10.1002/1097-0142(197011)26:5&lt;1053::aidcncr2820260513&gt;3.0.co;2-x</mixed-citation><mixed-citation xml:lang="ru">Noguchi S., Noguchi A., Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 1970;26(5):1053–60. DOI: 10.1002/1097-0142(197011)26:5&lt;1053::aidcncr2820260513&gt;3.0.co;2-x</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Lang B.H., Chan D.T., Wong K.P. et al. Predictive factors and pattern of locoregional recurrence after prophylactic central neck dissection in papillary thyroid carcinoma. Ann Surg Oncol 2014;21(13):4181–7. DOI: 10.1245/s10434-014-3872-6</mixed-citation><mixed-citation xml:lang="ru">Lang B.H., Chan D.T., Wong K.P. et al. Predictive factors and pattern of locoregional recurrence after prophylactic central neck dissection in papillary thyroid carcinoma. Ann Surg Oncol 2014;21(13):4181–7. DOI: 10.1245/s10434-014-3872-6</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Vergez S., Sarini J., Percodani J. et al. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol 2010;36(8):777–82. DOI: 10.1016/j.ejso.2010.06.015</mixed-citation><mixed-citation xml:lang="ru">Vergez S., Sarini J., Percodani J. et al. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol 2010;36(8):777–82. DOI: 10.1016/j.ejso.2010.06.015</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Jeon M.J., Yoon J.H., Han J.M. et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol 2013;168(2):219–25. DOI: 10.1530/EJE-12-0744</mixed-citation><mixed-citation xml:lang="ru">Jeon M.J., Yoon J.H., Han J.M. et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol 2013;168(2):219–25. DOI: 10.1530/EJE-12-0744</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Kim S.T., Cheon B.K., Lee H.S. et al. Subclinical central lymph node metastasis in papillary thyroid microcarcinoma evaluated as cT1aN0 by preoperative imaging study. J Korean Thyroid Assoc 2013;6(2):121–5. DOI: 10.11106/jkta.2013.6.2.121</mixed-citation><mixed-citation xml:lang="ru">Kim S.T., Cheon B.K., Lee H.S. et al. Subclinical central lymph node metastasis in papillary thyroid microcarcinoma evaluated as cT1aN0 by preoperative imaging study. J Korean Thyroid Assoc 2013;6(2):121–5. DOI: 10.11106/jkta.2013.6.2.121</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Ahn J.E., Lee J.H., Yi J.S. et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 2008;32(7):1552–8. DOI: 10.1007/s00268-008-9588-7</mixed-citation><mixed-citation xml:lang="ru">Ahn J.E., Lee J.H., Yi J.S. et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 2008;32(7):1552–8. DOI: 10.1007/s00268-008-9588-7</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Tavares M.R., Cruz J.A., Waisberg D.R. et al. Lymph node distribution in the central compartment of the neck: an anatomic study. Head Neck 2014;36(10):1425–30. DOI: 10.1002/hed.23469</mixed-citation><mixed-citation xml:lang="ru">Tavares M.R., Cruz J.A., Waisberg D.R. et al. Lymph node distribution in the central compartment of the neck: an anatomic study. Head Neck 2014;36(10):1425–30. DOI: 10.1002/hed.23469</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Sadowski B.M., Snyder S.K., Lairmore T.C. Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery 2009;146(4):696–703. DOI: 10.1016/j.surg.2009.06.046</mixed-citation><mixed-citation xml:lang="ru">Sadowski B.M., Snyder S.K., Lairmore T.C. Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery 2009;146(4):696–703. DOI: 10.1016/j.surg.2009.06.046</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Calò P.G., Pisano G., Medas F. et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol 2014;12:152. DOI: 10.1186/1477-7819-12-152</mixed-citation><mixed-citation xml:lang="ru">Calò P.G., Pisano G., Medas F. et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol 2014;12:152. DOI: 10.1186/1477-7819-12-152</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Bilezikçi B., Ilgan S., Özbaş et al. The number of lymph nodes and relationship with presence of thyroiditis and thymic tissue in the central neck dissection materials for thyroid papillary carcinoma: pathologic analysis. Int J Clin Med 2016;7(9)566–76. DOI: 10.4236/ijcm.2016.79062</mixed-citation><mixed-citation xml:lang="ru">Bilezikçi B., Ilgan S., Özbaş et al. The number of lymph nodes and relationship with presence of thyroiditis and thymic tissue in the central neck dissection materials for thyroid papillary carcinoma: pathologic analysis. Int J Clin Med 2016;7(9)566–76. DOI: 10.4236/ijcm.2016.79062</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Hall C.M., Snyder S.K., Maldonado Y.M., Lairmore T.C. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence. Surgery 2016;160(4):1049–58. DOI: 10.1016/j.surg.2016.06.042</mixed-citation><mixed-citation xml:lang="ru">Hall C.M., Snyder S.K., Maldonado Y.M., Lairmore T.C. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence. Surgery 2016;160(4):1049–58. DOI: 10.1016/j.surg.2016.06.042</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Yoo H.S., Shin M.C., Ji Y.B. et al. Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma: comparison of unilateral versus bilateral central neck dissection. Asian J Surg 2018;41(4)363–9. DOI: 10.1016/j.asjsur.2017.03.002</mixed-citation><mixed-citation xml:lang="ru">Yoo H.S., Shin M.C., Ji Y.B. et al. Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma: comparison of unilateral versus bilateral central neck dissection. Asian J Surg 2018;41(4)363–9. DOI: 10.1016/j.asjsur.2017.03.002</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Zheng C.M., Ji Y.B., Song C.M. et al. Number of metastatic lymph nodes and ratio of metastatic lymph nodes to total number of retrieved lymph nodes are risk factors for recurrence in patients with clinically node negative papillary thyroid carcinoma. Clin Exp Otorhinolaryngol 2018;11(1):58–64. DOI: 10.21053/ceo.2017.00472</mixed-citation><mixed-citation xml:lang="ru">Zheng C.M., Ji Y.B., Song C.M. et al. Number of metastatic lymph nodes and ratio of metastatic lymph nodes to total number of retrieved lymph nodes are risk factors for recurrence in patients with clinically node negative papillary thyroid carcinoma. Clin Exp Otorhinolaryngol 2018;11(1):58–64. DOI: 10.21053/ceo.2017.00472</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15.	Swetter S.M., Thompson J.A., Albertini M.R. et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021;19(4):364–76. DOI: 10.6004/jnccn.2021.0018</mixed-citation><mixed-citation xml:lang="ru">Swetter S.M., Thompson J.A., Albertini M.R. et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021;19(4):364–76. DOI: 10.6004/jnccn.2021.0018</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16.	Pomorski L., Kaczka K., Piaskowski S. et al. Detection of lymph node metastases of papillary thyroid cancer-comparison of the results of histopathology, immunohistochemistry and reverse transcription-polymerase chain reaction – a preliminary report. Langenbecks Arch Surg 2005;390(3):209–15. DOI: 10.1007/s00423-004-0528-1</mixed-citation><mixed-citation xml:lang="ru">Pomorski L., Kaczka K., Piaskowski S. et al. Detection of lymph node metastases of papillary thyroid cancer-comparison of the results of histopathology, immunohistochemistry and reverse transcription-polymerase chain reaction – a preliminary report. Langenbecks Arch Surg 2005;390(3):209–15. DOI: 10.1007/s00423-004-0528-1</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Randolph G.W., Duh Q.Y., Heller K.S. et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012;22(11):1144–52. DOI: 10.1089/thy.2012.0043</mixed-citation><mixed-citation xml:lang="ru">Randolph G.W., Duh Q.Y., Heller K.S. et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012;22(11):1144–52. DOI: 10.1089/thy.2012.0043</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Hwangbo Y., Kim J.M., Park Y.J. et al. Long-term recurrence of small papillary thyroid cancer and its risk factors in a korean multicenter study. J Clin Endocrinol Metab 2017;102(2):625–33. DOI: 10.1210/jc.2016-2287</mixed-citation><mixed-citation xml:lang="ru">Hwangbo Y., Kim J.M., Park Y.J. et al. Long-term recurrence of small papillary thyroid cancer and its risk factors in a korean multicenter study. J Clin Endocrinol Metab 2017;102(2):625–33. DOI: 10.1210/jc.2016-2287</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Carty S.E., Cooper D.S., Doherty G.M. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19(11):1153–8. DOI: 10.1089/thy.2009.0159</mixed-citation><mixed-citation xml:lang="ru">Carty S.E., Cooper D.S., Doherty G.M. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19(11):1153–8. DOI: 10.1089/thy.2009.0159</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer longterm impact of initial therapy. Trans Am Clin Climatol Assoc 1995;106:151–68.</mixed-citation><mixed-citation xml:lang="ru">Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer longterm impact of initial therapy. Trans Am Clin Climatol Assoc 1995;106:151–68.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21.	Noguchi S., Yamashita H., Uchino S., Watanabe S. Papillary microcarcinoma. World J Surg 2008;32(5):747–53. DOI: 10.1007/s00268-007-9453-0</mixed-citation><mixed-citation xml:lang="ru">Noguchi S., Yamashita H., Uchino S., Watanabe S. Papillary microcarcinoma. World J Surg 2008;32(5):747–53. DOI: 10.1007/s00268-007-9453-0</mixed-citation></citation-alternatives></ref></ref-list></back></article>
